Kalydeco Seen as Safe in Treating Young Children, Ages 1 to 2, in Phase 3 Trial, Vertex Reports
Kalydeco (ivacaftor) is safe and effective in 1- and 2-year-olds with cystic fibrosis (CF), Vertex Pharmaceuticals reported based on data...
Europe’s CHMP Gives Its Blessing to Vertex’s Orkambi as CF Therapy for Younger Children
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Orkambi...
Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Li
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and...
#NACFC2017 – Latest Trial Data on Vertex CF Therapies and New Combos Show Benefits
Vertex Pharmaceuticals recently presented data from several clinical trials of cystic fibrosis treatments showing positive outcomes for...